NICE. (v) Healthwatch England and Local Healthwatch; (vi) the General Medical Council; (vii) the General Dental Council; (viii) the General Optical Council; (ix) the General Pharmaceutical Council; (x) the Healthcare Safety Investigation Branch; and (xi) the Information Commissioner; Relevant Information means the Personal Data and Non-Personal Data processed under the Delegation and this Agreement, and includes, where appropriate, “confidential patient information” (as defined under section 251 of the NHS Act), and “patient confidential information” as defined in the 2013 Report, The Information Governance Review – “To Share or Not to Share?”);
NICE. 3.1.5 Locally defined objectives include: Delivery of efficiencies to address the Health and Social Care financial challenge.
NICE. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]Published date: 14 March 2018 Last updated: 13 September 2019. Available at: xxxxx://xxx.xxxx.xxx.xx/guidance/ng87 [Accessed June 2020] NICE. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release. Evidence summary [ESNM70] 22 March 2016. Available at: xxxxx://xxx.xxxx.xxx.xx/advice/esnm70/chapter/Key-points-from-the-evidence [Accessed May 2020]
NICE. Maintenance and monitoring for people taking medication for ADHD. Last Updated September 2019. Available at: xxxxx://xxxxxxxx.xxxx.xxx.xx/pathways/attention-deficit-hyperactivity-disorder#path=view%3A/pathways/attention-deficit-hyperactivity-disorder/maintenance-and-monitoring-for-people-taking-medication-for-adhd.xml&content=view-info-category%3Aview-resources-menu [Accessed June 2020] Joint Formulary Committee. British National Formulary for Children (BNFc). May 2020 Available at: xxxxx://xxxx.xxxx.xxx.xx/ [Accessed May 2020] Electronic Medicines Compendium. Summaries of Product Characteristics. Available at: xxxxx://xxx.xxxxxxxxx.xxx.xx/emc [Accessed June 2020] General Medical Council. Prescribing Unlicensed Medicines. Available at: xxxxx://xxx.xxx-xx.xxx/ethical-guidance/ethical-guidance-for-doctors/prescribing-and-managing-medicines-and-devices/prescribing-unlicensed-medicines [Accessed 17.6.20] NHS England. Responsibility for prescribing between Primary & Secondary/Tertiary Care. Publications Gateway Reference 07573. January 2018. Available at: xxxxx://xxx.xxxxxxx.xxx.xx/wp-content/uploads/2018/03/responsibility-prescribing-between-primary-secondary-care-v2.pdf [Accessed June 2020]
NICE. (e) Healthwatch England and Local Healthwatch; (f) Public Health England; (g) the General Pharmaceutical Council; (h) the Healthcare Safety Investigation Branch; (i) Information Commissioner; (j) European Data Protection Board; Special Categories of Personal Data As defined in Article 9 of the UK GDPR - Personal Data revealing: (a) racial or ethnic origin (b) political opinions (c) religious or philosophical beliefs (d) trade union membership (e) genetic data or biometric data identifying a natural person (f) data concerning health (g) data concerning a natural person's sex life or sexual orientation
NICE may assign this XXXX without your consent (i) in connection with a merger, acquisition or sale of all or substantially all of our assets, or (ii) to any affiliate or as part of a corporate reorganization; and effective upon such assignment, the assignee is deemed substituted for NICE as a party to this XXXX and NICE is fully released from all of its obligations and duties to perform under this XXXX. Subject to the foregoing, this XXXX will be binding upon, and inure to the benefit of the parties and their respective permitted successors and assigns.
NICE. Principles for Best Practice in Clinical Audit. 2002.
NICE. 59.1.1 The Provider will deliver the service in accordance with NICE (2008 updated in 2014 and any subsequent revision) guidance.
NICE. 2. Details of Lithium salts are available in several different preparations and must always be prescribed by medicine and brand name because of the different bioavailability of the preparations. The preferred indication Please state whether licensed or unlicensed (off-label) use. Note that shared care is generally unsuitable for off-label prescribing unless it is a widely recognised use (e.g. included in BNF) preparation in AWP is Priadel® as it allows more tailored dosing than the alternatives. Lithium salts are licensed to be used for the conditions listed in section 1, apart from for the management of recurrent depression as augmentation of antidepressants, which is an unlicensed use. Priadel® (lithium carbonate) 200mg modified-release tablets 400mg modified-release tablets Tablets are scored, can be broken in half to aid dose adjustment Priadel® liquid (lithium citrate 520mg/5ml oral syrup) Lithium citrate 520mg is equivalent to lithium carbonate 204mg Li-Liquid® (lithium citrate) NB two strengths available Lithium citrate tetrahydrate 509mg/5ml oral syrup Lithium citrate tetrahydrate 1018mg/5ml oral syrup Lithium citrate tetrahydrate 509mg is equivalent to lithium carbonate 200mg Other preparations available: Liskonum (lithium carbonate) 450mg modified-release tablets Camcolit (lithium carbonate) 400mg modified-release tablets Lithium carbonate (Essential Pharma/Alliance/AAH) 250mg tablets
NICE. (2006). Dementia: Supporting people with Dementia and Their Carers in Health and Social Care. London: National Institute of Health and Care Excellence. Ormel, X., Xxxxxx, X., & Xxxxx, V. (1989). Measuring Change with the General Health Questionnaire. Social Psychiatry and Psychiatric Epidemiology, 24, 227-232. Xxxxxxxx, X., Xxxxxxxxx, X., Xxxx, X., Xxx, X., & Xxxxxxx, D. (2009). Symptoms of depression in non-routine caregivers: The role of caregiver strain and burden. British Journal of Clinical Psychology, 48, 335-346. Xxxxxxxx, X., & Xxxxxxxx, S. (2006). Helping Caregivers of Persons with dementia: Which Interventions Work and How Large Are Their Effects? International Psychogeriatics, 18(4), 577-595. Xxxxxx, X., Xxxx, M., Xxxxxxxx, R., & Xxxxxxx, M. (1994). The establishment of clinical cutoffs in measuring caregiver burden in dementia. The Gerontologist, 34, 828-832. Xxxxxx, X., & Xxxxx, R. (2005). Cognitive behavioural therapy (CBT) for carers of patients with Xxxxxxxxx'x disease: a preliminary randomised control trial. Journal of Neurology, Neurosurgery and Psychiatry, 76, 491-497. Xxxxxxx, X., Xxxxx, X., & Xxxx, D. (2002). Frontotemporal Dementia. British Journal of Psychiatry, 180, 140-143. Xxxxxxxx, S., Xxxxxxxx, M., Xxxxx, X., & Xxxxxxxxxx, P. (2002). How Effective Are Interventions With Caregivers? An Updated Meta-Analysis. The Gerontologist, 42(3), 356-372. Xxxxxxxx, X., Xxxxxxxx-Xxxxxx, M., Xxxxx, X., Xxxxx, E., Wollersheim, H., Xxxx, R., et al. (2008). Effectiveness of Nonpharmacological Interventions in Delaying the Institutionalization of Patients with Dementia: A Meta-Analysis. Journal of American Geriatric Society, 56, 1116-1128.
